Skip to content

Study of nirgundi and hadjod base formulation on knee joint ostioarthritis

A clinical study to evaluate the efficacy of Nirgundi and Hadjod based oral and topical formulation on knee joints of osteoarthritic patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/043798
Enrollment
60
Registered
2022-07-07
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

Intervention1: NIRGUNDI AND HADJOD BASE ORAL AND TROPICAL FORMULATION: NIRDUNGI AND HADJOD WATER DISPENSER POWER ORALLY 500 MG BD AND LOCAL APPLICATION OF TROPICAL FORMULATION TWICE A DAY FOR 6 WEEKS.

Sponsors

CSIR NEW DELHI HCP
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Volunteers with affected joints,who are willing to undergo the treatment. Age between 40 -70 years. Individuals who are willing and able to participate for 6 months of duration.

Exclusion criteria

Exclusion criteria: Patients not willing for trial. Patients below the age of 40 years and above 70 years. Patients who have participated in any clinical trial during past 6 months. Subjects with cardiac problems. Subjects with uncontrolled diabetes mellitus Subjects with multiple joint disorders. Subjects with advanced rheumatoid arthritis. Subject advanced knee osteoarthritis. Subjects suffering from major systemic illness necessitating long term drug treatment (R.A, PTB, malignancy etc.) Any other condition which the Investigator thinks may compromise the safety of the subject

Design outcomes

Primary

MeasureTime frame
Improvement will be evaluated by objective evaluation of knee joints (affected joint or both joints) (mandatory); X-ray and MRI depending upon availability. It will be done to check the efficacy of the productOSTEOARTHRITIS PATIENT. EFFECT ON CHOLEGEN HEALTHTimepoint: 8 WEEKS

Secondary

MeasureTime frame
Other parameters such as Complete Blood Count, ESR, Liver function test, renal function test etc will be evaluated to check safety and any adverse effect on the patient.Timepoint: 8 WEEKS

Countries

India

Contacts

Public ContactDR ANIL KUMAR SHARMA

R G GOVT P G AYURVEDIC COLLEGE PAPROLA

dranilpaprola@gmail.com9805056393

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026